Cytoprime2 Study Proves Effectiveness of EndoSign® Capsule Sponge Test in Community Care for Early Detection of Esophageal Cancer
Cyted Health today announces the publication of its article, “Feasibility of primary care-based early detection of Barrett’s oesophagus and oesophageal adenocarcinoma in patients with reflux using capsule sponge testing: real-world insights from the CYTOPRIME 2 Study” in Frontline Gastroenterology, the peer-reviewed official publication of the British Society of Gastroenterology and the British Medical Journal.
The CYTOPRIME 2 Study, commissioned and funded by the NHS Cancer Programme, with the support of SBRI Healthcare and the Accelerated Access Collaborative, was designed to assess the feasibility of implementing capsule sponge testing, EndoSign®, with biomarkers in a real-world community care setting for the earlier detection of Barrett’s Esophagus (BE), supporting intervention to prevent the development of late-stage esophageal adenocarcinoma (EAC) and improve survival rates.
More than 1,800 patients with chronic gastro-esophageal reflux disease (GERD) were identified through primary care records and invited for a capsule sponge test in a community setting.
The data published supports the use of minimally invasive capsule sponge testing in a community setting for the diagnosis of BE and late-stage EAC in a target population of patients with GERD. This enables patients diagnosed with BE to be offered risk-based surveillance to detect precancerous changes and target endoscopic therapies to prevent late-stage EAC.
“The CYTOPRIME 2 Study has shown that capsule sponge testing is an effective method for detecting BE and EAC in primary care,” Dr Marcel Gehrung, CEO and Co-founder of Cyted Health, commented. “The results will be used to further expand the use of EndoSign® in the community, equipping primary care providers with a diagnostic tool that expands patient access and improves the earlier detection of EAC”.
In September 2025, Cyted secured $44 million in Series B financing to accelerate its US expansion. This follows the launch of its DETECT-ME clinical validation study, which has been enrolling patients across multiple sites in the US since March 2025. The study is validating the clinical performance of Cyted’s newest assays and molecular tests for the detection of esophageal conditions using EndoSign®.
